Goldman Sachs’s CELATOR PHARMACEUTICALS INC. COMMON STOCK CPXX Stock Holding History

Goldman Sachs’s Portfolio CPXX Stock Details CPXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-323,663	Closed	-$9.77M	–	7412
2016 Q2	$9.77M	Buy	323,663 +245,481	+314%	+$4.98M	﹤0.01%	2342
2016 Q1	$862K	Buy	+78,182	New	+$256K	﹤0.01%	4199
2015 Q4	–	Sell	-34,795	Closed	-$58K	–	7565
2015 Q3	$58K	Buy	+34,795	New	+$77.2K	﹤0.01%	6740
2015 Q2	–	Sell	-11,550	Closed	-$29K	–	7592
2015 Q1	$29K	Buy	+11,550	New	+$31.1K	﹤0.01%	6845

Goldman Sachs's CPXX Position: Q3 2016 in Review

Goldman Sachs sold out of CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) in Q3 2016, closing a stake of 323,663 shares — an estimated $9.77M sold.

Goldman Sachs first reported a position in CPXX in Q1 2015 and held it in 4 quarters. The position peaked at $9.77M in Q2 2016. 0 funds tracked by Wall St. Rank hold CPXX as of Q3 2016.

Goldman Sachs reported no remaining CELATOR PHARMACEUTICALS INC. COMMON STOCK position as of Q3 2016 after selling out during the quarter.
Goldman Sachs sold 323,663 CELATOR PHARMACEUTICALS INC. COMMON STOCK shares in Q3 2016, an estimated $9.77M.
Goldman Sachs first reported a position in CELATOR PHARMACEUTICALS INC. COMMON STOCK in Q1 2015 and held it in 4 quarters.
Goldman Sachs's CELATOR PHARMACEUTICALS INC. COMMON STOCK position peaked at $9.77M in Q2 2016.
0 funds tracked by Wall St. Rank held CELATOR PHARMACEUTICALS INC. COMMON STOCK as of Q3 2016.

Based on Goldman Sachs's 13F filing for Q3 2016, filed 14 Nov 2016.